Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
#junkfluenced: the marketing of unhealthy food and beverages by social media influencers popular with Canadian children on YouTube, Instagram and TikTok
Marketing of unhealthy foods to children on digital media significantly impacts their dietary preferences and contributes to diet-related noncommunicable diseases. Canadian children spend a significant amount ... (Source: International Journal of Behavioral Nutrition and Physical Activity)
Source: International Journal of Behavioral Nutrition and Physical Activity - April 11, 2024 Category: Nutrition Authors: Monique Potvin Kent, Mariangela Bagnato, Ashley Amson, Lauren Remedios, Meghan Pritchard, Soulene Sabir, Grace Gillis, Elise Pauz é, Lana Vanderlee, Christine White and David Hammond Tags: Research Source Type: research
Rationalising Optimal Dosing of Phytotherapeutics For Use In Children: Current Status – Potential Solutions – Actions Needed
Planta Med DOI: 10.1055/a-2294-5259“Children are not small adults with respect to the treatment with medicinal products.” This statement of the WHO was the basis for the initiative of the European Commission for the establishment of a paediatric regulation in 2007 to improve the health of children by facilitating the development of medicines for children and adolescents. Seventeen years later, in the field of herbal medicinal products, results are still sobering. Therefore, the Foundation Plants for Health, Society for Medicinal Plants and Natural Products Research, and German Society for Phytotherapy organised a sympo...
Source: Planta Medica - April 11, 2024 Category: Drugs & Pharmacology Authors: Hensel, Andreas Bauer, Rudolf Heinrich, Michael Hempel, Georg Kelber, Olaf Kraft, Karin Lehmann, Birka Med à, Montserrat Mesegué Nieber, Karen Roether, Bernd Rollinger, Judith Maria Wiebelitz, R üdiger Tags: Perspectives Source Type: research
A Systematic Literature Review of Substance-Use Prevention Programs Amongst Refugee Youth
Community Ment Health J. 2024 Apr 9. doi: 10.1007/s10597-024-01267-6. Online ahead of print.ABSTRACTThis paper aims at exploring existing literature on substance use prevention programs, focusing on refugee youth. A comprehensive search for relevant articles was conducted on Scopus, PubMed, and EBSCOhost Megafile databases including Academic Search Ultimate, APA PsycArticles, APA PsycInfo, CINAHL with Full Text, E-Journals, Humanities Source Ultimate, Psychology and Behavioural Sciences Collection, and Sociology Source Ultimate. Initially, a total of 485 studies were retrieved; nine papers were retained for quality assessm...
Source: Community Mental Health Journal - April 9, 2024 Category: Psychiatry Authors: Elijah Aleer Khorshed Alam Afzalur Rashid Source Type: research
Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Clin Pharmacol Ther. 2024 Apr 8. doi: 10.1002/cpt.3258. Online ahead of print.ABSTRACTTranslational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with ...
Source: Clinical Pharmacology and Therapeutics - April 9, 2024 Category: Drugs & Pharmacology Authors: Elpida Kontsioti Simon Maskell Isobel Anderson Munir Pirmohamed Source Type: research
Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Clin Pharmacol Ther. 2024 Apr 8. doi: 10.1002/cpt.3258. Online ahead of print.ABSTRACTTranslational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with ...
Source: Clinical Pharmacology and Therapeutics - April 9, 2024 Category: Drugs & Pharmacology Authors: Elpida Kontsioti Simon Maskell Isobel Anderson Munir Pirmohamed Source Type: research
A Systematic Literature Review of Substance-Use Prevention Programs Amongst Refugee Youth
Community Ment Health J. 2024 Apr 9. doi: 10.1007/s10597-024-01267-6. Online ahead of print.ABSTRACTThis paper aims at exploring existing literature on substance use prevention programs, focusing on refugee youth. A comprehensive search for relevant articles was conducted on Scopus, PubMed, and EBSCOhost Megafile databases including Academic Search Ultimate, APA PsycArticles, APA PsycInfo, CINAHL with Full Text, E-Journals, Humanities Source Ultimate, Psychology and Behavioural Sciences Collection, and Sociology Source Ultimate. Initially, a total of 485 studies were retrieved; nine papers were retained for quality assessm...
Source: Community Mental Health Journal - April 9, 2024 Category: Psychiatry Authors: Elijah Aleer Khorshed Alam Afzalur Rashid Source Type: research
